Axinn attorneys succeeded in obtaining a denial of a TRO motion that had sought an order to keep Axinn client Zydus from marketing its generic version of Abilify (aripiprazole). Abilify is a multi-billion dollar drug marketed by Otsuka, and Otsuka sought a ruling from the United States District Court for the District of New Jersey that the marketing of Zydus’ generic aripiprazole product would infringe Otsuka’s patent. The Axinn team included Chad Landmon, Delphine Knight-Brown, Jason Murata, and Brett Garrison. Additionally, the firm was joined by a number of other defendants in opposing Otsuka’s TRO motion.
Axinn Obtains Denial of a TRO Motion for Client Zydus
April 23, 2015